目的 观察培养的人脑胶质瘤组织对临床常用化疗药物的敏感性,为胶质瘤的个体化治疗提供实验依据。 方法 利用112例脑胶质瘤标本进行组织块体外培养,观察其对临床脑胶质瘤治疗常用药物尼莫司汀(ACNU)、顺铂(DDP)、替莫唑胺(TMZ)、长春新碱(VCR)、替尼泊苷(VM26)及组合用药DDP＋VM26的敏感性,比较化疗药物体外抗肿瘤作用的差异;分析化疗药物敏感性与患者病理分级的相关性;应用透射电镜观察化疗药物作用前后肿瘤组织超微结构的变化。 结果 人脑胶质瘤培养组织对化疗药物的敏感性依次为DDP＋VM26、VM26、TMZ、VCR、DDP和ACNU;仅组合用药DDP＋VM26的敏感性与患者病理分级有关(χ2=4.447,P=0.035);透射电镜观察发现化疗药物作用后肿瘤细胞呈凋亡中晚期改变及坏死的变化。 结论 不同人脑胶质瘤培养组织对化疗药物的敏感性存在差异,引起肿瘤细胞凋亡或坏死可能是化疗药物发挥作用的机制之一。
Abstract
Objective To select chemotherapeutic agents based on in vitro chemosensitivity test of glioma in tissue culture in order to provide experimental data for individualized treatment of glioma.Methods One hundred and twelve specimens resected from brain glioma were used to evaluate the in vitro chemosensitivity of glioma with tissue culture. Six chemotherapeutic agent groups against brain cancer were designed, which were nimustine (ACNU), cisplatin (DDP), temozolomide (TMZ) , vincristine (VCR), teniposide (VM26) and DDP＋VM26. The ultrastructural changes of brain glioma after exposure to chemotherapeutic agents were observed under an electron microscope. Furthermore, the correlations between drug chemosensitivity and patients’ pathological grade were analyzed.Results The chemosensitivity of DDP＋VM26 group and VM26 group was significantly higher than that of the other four groups (P＜0.003). Under an electron microscope, the glioma cells showed apoptosis and necrosis changes after exposure to chemotherapeutic agents. The chemosensitivity of DDP＋VM26 group was correlated with the pathological grade of patients (χ2=4.447, P=0.035).Conclusions The sensitivity of patients with different glioma to chemotherapeutic drugs is different, and the apoptosis or necrosis of tumor cells may be one of the mechanisms of chemotherapeutic drugs.
关键词
胶质瘤 /
体外化疗药物敏感性试验 /
组织块培养法 /
电镜
Key words
glioma /
in vitro chemosensitivity test /
tissue culture /
electron microscope
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Alifieris C, Trafalis D T. Glioblastoma multiforme: Pathogenesis and treatment [J]. Pharmacol Ther, 2015, 152: 63-82.
[2] 张 伟,江 涛,袁 芳, 等.脑胶质瘤组织培养化疗药物敏感性的研究[J].中国微侵袭神经外科杂志, 2007, 12(4):163-166.
[3] Singh B, Li R, Xu L, et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay [J]. Head Neck, 2002, 24(5): 437-442.
[4] 黄世明,罗燕薇,李彦峰,等. 18F-FDOPA与18F-FDG PET/CT诊断脑肿瘤的系统评价[J].武警医学, 2017, 28(6): 573-577.
[5] Batash R, Asna N, Schaffer P, et al. Glioblastoma multiforme, diagnosis and treatment; recent literature review[J]. Curr Med Chem, 2017, 24(27):3002-3009.
[6] Furukawa T, Kubota T, Hoffman R M. Clinical applications of the histoculture drug response assay[J]. Clin Cancer Res, 1995,1(3):305-311.
[7] 于朝春,周范民,王宇倩,等.脑胶质瘤的化疗敏感性研究[J]. 中华神经医学杂志, 2005, 4(7):686-690.
[8] 张惊宇,张力娜,郑永慧,等.体外原代培养脑胶质瘤细胞对化疗药物敏感性的影响[J].中国老年学杂志, 2015,35(21):6023-6024.
[9] Anjum K, Shagufta B I, Abbas S Q, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review[J]. Biomed Pharmacother, 2017, 92: 681-689.
[10] 徐 荣,华 咏,钟 平,等.替尼泊苷诱导脑胶质瘤细胞凋亡的检测指标评估[J].中国临床神经科学, 2010,18(2):156-160.
[11] 李 岩,石 蕊,陈建新,等.VM-26和DDP联合化疗对复发高级别脑胶质瘤的治疗体会[J]. 首都医科大学学报, 2015,36(5):786-790.
[12] 曹广辉,谭卫国,冯 鸣, 等.VM26联合MeCCNU在人脑低级别胶质瘤治疗中应用的初步探讨[J].临床神经外科杂志, 2011, 8(1):10-12.
基金
北京市自然科学基金项目(7102028);北京市自然科学基金项目(7152027)
PDF(1142 KB)
